About

Our lab aims to develop highly translational immunotherapies.
We work on bi-specific antibodies, tri- specifics cytokine-antibody fusion proteins, engineered cytokines, CAR-T cells, TCR-T cells, and mRNA therapeutics. We utilise an artificial intelligence AI-driven drug discovery method.

We work in a team-based setting that facilitates immersion and discussion of issues in the clinic. Our state-of-the-art equipment enables efficient data gathering and the generation of novel drugs. We have 23-colour flow cytometry, a Cellcyte cell culture imager, BLI, a haematology analyser, a biochemistry analyser, six shakers for protein production, real-time PCR, a gel imager, a Nanodrop, a plate reader, and a histology scanner. Our core facility access includes Imperial's bacteria and tissue culture facilities, an animal research facility, a genomics facility, and a microscope facility.
Working in close collaboration with other laboratories fosters strong and multidisciplinary work.

Through our protein and cellular engineering approaches, we are working to make impactful discoveries that can be translated into clinical applications to improve human health.

Our research areas include cancer, regenerative medicine and autoimmune diseases.

We thank the funders. Together, we will create novel therapeutics that are highly effective, have minimal side effects, and are patient-friendly. Our lab is supported by Crowdfunding, MRC, Cancer Research UK, US department of defense, The Academy of Medical Sciences (acmedsci.ac.uk/), Pancreatic Cancer UK(pancreaticcancer.org.uk/), Prostate Cancer UK(prostatecanceruk.org/), Sarcoma UK(sarcoma.org.uk/), Rose tree trust, The Royal Society, and Pancreatic Cancer Research Fund (pcrf.org.uk/), The brain tumour charity (https://www.thebraintumourcharity.org/), the Institute for Cancer Vaccines and Immunotherapy (https://icvi.org.uk/), Little Princes Trust (https://www.littleprincesses.org.uk/)